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Abstract (249/250) 
Background: nab-Paclitaxel has demonstrated efficacy in adults with solid tumors and 
preclinical activity in pediatric solid tumor models. Results from phase I of a phase I/II 
study in pediatric patients with recurrent/refractory solid tumors treated with nab-
paclitaxel are reported.  
Patients and methods: Patients with recurrent/refractory extracranial solid tumors 
received nab-paclitaxel on days 1, 8, and 15 every 4 weeks at 120, 150, 180, 210, 240, 
or 270 mg/m2 (rolling-6 dose-escalation) to establish the maximum tolerated dose 
(MTD) and recommended phase II dose (RP2D).  
Results: Sixty-four patients were treated. Dose-limiting toxicities were grade 3 
dizziness at 120 mg/m2 and grade 4 neutropenia >7 days at 270 mg/m2. The most 
frequent grade 3/4 adverse events were hematologic, including neutropenia (36%), 
leukopenia (36%), and lymphopenia (25%). Although the MTD was not reached, 270 
mg/m2 was declared nontolerable due to grade 3/4 toxicities during cycles 1-2 
(neutropenia, n=5/7; skin toxicity, n=2/7; peripheral neuropathy, n=1/7). Of 58 efficacy-
evaluable patients, complete response occurred in 1 patient (2%; Ewing sarcoma) and 
partial responses in 4 patients (7%; rhabdomyosarcoma, Ewing sarcoma, renal tumor 
with pulmonary metastases [high-grade, malignant], and sarcoma not otherwise 
specified); all responses occurred at ≥210 mg/m2. Thirteen patients (22%) had stable 
disease (5 lasting ≥16 weeks) per RECIST.  
Conclusions: nab-Paclitaxel 240 mg/m2 qw3/4 (nearly double the adult recommended 
monotherapy dose for this schedule in metastatic breast cancer) was selected as the 
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RP2D based on the tolerability profile, pharmacokinetics, and antitumor activity. Phase 
II is currently enrolling patients with recurrent/refractory neuroblastoma, 
rhabdomyosarcoma, and Ewing sarcoma.  
ClinicalTrials.gov: NCT01962103 
EudraCT: 2013-000144-26 
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Introduction 
Cancer is a leading cause of childhood death in developed countries [1]. Despite 
a relatively high combined survival rate for childhood cancers, recurrent/refractory 
disease is common in pediatric patients with certain solid tumor types, such as 
metastatic sarcoma and high-risk neuroblastoma, and long-term outcomes are poor [2-
6]. Therefore, effective treatment options are needed. 
Solvent-based taxanes have demonstrated antitumor activity in children with 
refractory solid tumors. However, their use has been compromised by dose-limiting 
toxicities (DLTs) that, in some cases, may result from the solvent-based formulation of 
these agents [7-9]. In a phase I trial, paclitaxel treatment resulted in DLTs, including 
acute neurological toxicities such as coma and possibly severe allergic toxicity, as well 
as delayed peripheral neurotoxicity potentially attributable to both the ethanol and 
polyethoxylated castor oil or polysorbate 80 components of solvents [7]. In a phase I 
study, docetaxel treatment resulted in dose-limiting neutropenia in heavily and less-
heavily pretreated children with refractory solid tumors [8]. Similarly, in 2 phase I trials of 
>60 pediatric patients with refractory solid tumors, docetaxel administration resulted in 
dose-limiting neutropenia and desquamative dermatitis [9].  
nab-Paclitaxel, an albumin-bound form of paclitaxel, is ethanol free and may be a 
feasible treatment option for pediatric patients with refractory/relapsed solid tumors 
because it was designed to increase antitumor activity and reduce toxicities, including 
hypersensitivity reactions [10, 11]. Further, compared with conventional paclitaxel, nab-
paclitaxel has demonstrated enhanced transport across endothelial cell monolayers, 
faster and deeper tissue penetration, and slower elimination of paclitaxel [11, 12]. 
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Regimens containing nab-paclitaxel have demonstrated safety and efficacy in adults 
with various solid tumor types [10, 11, 13-16]. nab-Paclitaxel has been approved in the 
US and Europe for the treatment of metastatic breast cancer after failure of prior 
treatment, for the treatment of advanced non-small cell lung cancer in combination with 
carboplatin, and for the treatment of metastatic pancreatic cancer in combination with 
gemcitabine [10, 17]. nab-Paclitaxel received its first indication as a single agent in 
metastatic breast cancer at a dose of 260 mg/m2 every 3 weeks [10]. In adults with 
early-stage breast cancer, nab-paclitaxel monotherapy has also demonstrated efficacy 
at 125 mg/m2 weekly (3 of 4 weeks; qw3/4) [18]. Single-agent nab-paclitaxel has 
displayed dose-dependent cytotoxicity in several pediatric solid-tumor cell lines and 
antitumor activity in rhabdomyosarcoma, neuroblastoma, and Ewing sarcoma mouse 
xenograft models, supporting its clinical exploration in pediatric solid tumor 
malignancies [19, 20]. 
This phase I/II dose-finding study, conducted in collaboration with the Innovative 
Therapies for Children with Cancer European Consortium, is evaluating the safety, 
tolerability, and efficacy of weekly nab-paclitaxel in pediatric patients with 
recurrent/refractory solid tumors. Phase I results describing the nab-paclitaxel maximum 
tolerated dose (MTD), recommended phase II dose (RP2D), safety, pharmacokinetic 
profile, and preliminary clinical activity are reported here.  
 
Patients and Methods 
Study Population 
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 Pediatric patients ≥6 months to <18 years of age with recurrent/refractory solid 
tumors were enrolled. The study included patients whose disease progressed on 
standard therapy or for whom no standard therapy exists. Key eligibility criteria included 
a Lansky/Karnofsky performance status of ≥70, adequate bone marrow function 
(absolute neutrophil count [ANC] ≥1.0 × 109/L, platelets ≥80 × 109/L, hemoglobin ≥8 
g/dL), and adequate organ function (ie, aspartate aminotransferase, alanine 
aminotransferase ≤2.5 × upper limit of normal range [ULN], total bilirubin ≤1.5 × ULN, 
creatinine ≤1.5 × ULN). Patients with primary brain tumors, active/untreated brain 
metastasis, or baseline peripheral neuropathy grade ≥2 were excluded.  
 This study was conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice Guidelines of the International Conference on Harmonisation. 
Informed consent/assent was obtained from all patients or legal representatives 
(parents/guardians) prior to study entry. The trial is registered with ClinicalTrials.gov 
(NCT01962103) and EudraCT (2013-000144-26).  
Study Design 
 Phase I of this multicenter, open-label, dose-finding study, which was conducted 
at 16 sites across Europe, the United States, and Canada, used a rolling-6 dose-
escalation design to establish the MTD and RP2D of nab-paclitaxel [21]. The first 
patient was enrolled in December of 2013, and follow-up remains ongoing. Patients 
received nab-paclitaxel on days 1, 8, and 15 of a 28-day cycle (qw3/4) at 120 mg/m2 
(starting dose equivalent to 80% of the adult MTD corrected for body surface area), 150, 
180, 210, 240, or 270 mg/m2 doses. In any given dose-level cohort, if ≥2 patients 
experienced a DLT, the MTD was considered exceeded and the previous lower dose 
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declared the MTD. Patients enrolled while awaiting cohort DLT evaluation were treated 
at the previously declared safe dose level in order to avoid suspending recruitment. 
Patients enrolled under these circumstances were not considered for identification of 
the MTD/RP2D, but were included in safety, pharmacokinetic, and efficacy analyses.    
Decisions on dose escalation, MTD/RP2D, and study continuation were 
determined by the Safety Monitoring Committee, which included an academic lead, site 
investigators, the Celgene clinical research physician and research scientists, and the 
product-safety physician.  
Study Assessment 
 The phase I primary endpoints were the incidences of DLTs and treatment-
emergent adverse events (AEs). Secondary endpoints included pharmacokinetics and 
overall response rate (ORR) per Response Evaluation Criteria In Solid Tumors 
(RECIST) v1.1 [22]. Exploratory endpoints were response by 
123metaiodobenzylguanidine (MIBG) scintigraphy using Curie score [23] for patients with 
neuroblastoma and biomarker analyses in archival tumor tissue. A post hoc analysis 
using recently updated International Neuroblastoma Response Criteria (INRC) was also 
conducted [24]. See Supplemental Methods for details on the efficacy-evaluable 
population and response assessments. 
Treatment was given until disease progression, death, withdrawal of consent, or 
unacceptable toxicity. Safety was assessed in all treated patients. AEs were classified 
by the Medical Dictionary for Regulatory Activities v18.1, and severity was assessed per 
the National Cancer Institute’s Common Terminology Criteria for Adverse Events v4.0. 
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Dose reductions, delays, discontinuations, and clinical laboratory data were also 
evaluated.  
The MTD/RP2D determination was performed on the dose-determining set, 
which included patients treated in the 6 dose levels who had adequate safety 
assessments during the DLT assessment period and either experienced a DLT or 
received all 3 weekly nab-paclitaxel doses in the first cycle. A DLT was defined as a 
treatment-related AE occurring within the first cycle of treatment that led to treatment 
discontinuation or met 1 of the following criteria: grade 3/4 nonhematologic AE 
(excluding transient transaminitis), grade 3/4 nausea or vomiting lasting >5 days despite 
antiemetic treatment, grade 4 thrombocytopenia or anemia that persists >7 days or 
requires transfusion >7 days, grade 3 thrombocytopenia with bleeding, grade 4 
uncomplicated neutropenia lasting >7 days, febrile neutropenia with confirmed bacterial 
infection, or grade 3 hematologic toxicity delaying treatment >21 days. Granulocyte 
colony-stimulating factors were not permitted during the DLT assessment period but 
were subsequently allowed per institutional guidelines for the treatment of neutropenia. 
 
Results 
Patients 
 Phase I enrolled 65 patients; 64 patients aged 2 to 17 years were treated, and 1 
patient withdrew before treatment. Thirty-seven patients were enrolled in 6 dose levels 
and formed the dose-determining set (6 patients in each dose level except for 270 
mg/m2, which included 7 patients), and 27 patients were enrolled outside of the 
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specifications required for the dose-determining set (ie, during the periods in which 
placement in 1 of the 6 dose-determining cohorts was not available (Figure 1). Most 
patients (69%) had a Lansky/Karnofsky performance status of 90 to 100 (Table 1). 
Diagnoses included rhabdomyosarcoma (22%), Ewing sarcoma (20%), neuroblastoma 
(16%), and other less-frequent tumor types. All patients weighed >10 kg. The median 
number of prior treatment lines was 3.   
Treatment Exposure and Selection of the Recommended Phase II Dose 
In all treated patients, a median of 2 (range, 1-12) cycles were administered. 
Overall, the median treatment duration was 7.0 weeks. All 64 patients discontinued 
treatment; of these, 35 (55%) discontinued due to progressive disease (PD), 11 (17%) 
due to AEs, 11 (17%) due to clinical symptomatic deterioration, 5 (8%) due to 
withdrawal by patient or parent/guardian, and 1 (2%) due to physician decision.  
Protocol-defined DLTs were grade 3 dizziness (1 patient at the 120 mg/m2 dose 
level) and grade 4 neutropenia lasting >7 days (1 patient at the 270 mg/m2 dose level). 
Out of the 7 patients in the dose-determining set for the 270 mg/m2 dose, 4 patients 
continuing beyond cycle 1 required a dose reduction due to toxicity. Although DLT-
based criteria to determine the nontolerable dose were not met, the safety monitoring 
committee declared 270 mg/m2 as the nontolerable dose based on the totality of safety 
information, including grade 3/4 toxicities during the first 2 cycles (neutropenia, 5 of 7 
patients; skin toxicity, 2 of 7 patients; and peripheral neuropathy, 1 of 7 patients).  
Based on the combined safety, pharmacokinetic, and preliminary efficacy profiles 
of the 6 dose cohorts, nab-paclitaxel 240 mg/m2 was identified as the RP2D. 
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Safety 
Overall, 88% of the 64 patients experienced ≥1 treatment-emergent grade 3/4 
AE. At all tested dose levels, grade 3/4 AEs were mainly hematologic (Table 2). Two 
patients reported grade 3/4 peripheral neuropathy, one each receiving nab-paclitaxel 
240 and 270 mg/m2. Grade 3/4 hand-foot syndrome occurred in 2 patients, both of 
whom received nab-paclitaxel 270 mg/m2. Grade ≥2 peripheral neuropathy occurred in 
11% of patients, with a median time to onset of 62 days.  
Overall, 17% and 36% of patients had ≥1 nab-paclitaxel dose reduction or dose 
interruption, respectively. The nab-paclitaxel relative dose intensity was 99.6% in all 
cohorts combined (Table 3). 
Early nab-Paclitaxel Pharmacokinetic Profile 
  Based on an interim analysis, increased nab-paclitaxel blood exposure was 
approximately proportional to dose from 120 to 270 mg/m2, with mean area under the 
curve [AUC]24 ranging from 6392 to 11982 h•ng/mL, and mean maximum concentration 
(Cmax) ranging from 3488 to 8078 ng/mL. Between 240
 and 270 mg/m2, no difference 
was observed in mean AUC24 (11982 vs 9768 h•ng/mL) or mean Cmax (7910 vs 8078 
ng/mL), which could be accounted for by the small (12.5%) dose increment and 
interpatient variability. A full pharmacokinetic analysis will be conducted once data from 
phase II become available. 
Antitumor Activity Per RECIST 
 The efficacy population included 58 patients. Complete and partial responses 
occurred in 1/58 (2%) and 4/58 (7%) of patients, respectively (Table 4). The complete 
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response was observed in a patient with Ewing sarcoma, and partial responses were 
observed in patients with rhabdomyosarcoma, Ewing sarcoma, renal tumor with 
pulmonary metastases (high-grade malignant tumor not otherwise specified [NOS]), and 
sarcoma NOS. All responding patients were treated at doses ≥210 mg/m2. Stable 
disease was achieved in 13 patients (22%), 5 (9%) of whom had stable disease lasting 
for ≥16 weeks (1 patient with neuroblastoma and 2 each with Ewing sarcoma and 
sarcoma NOS). One patient with immature ovarian teratoma received 12 cycles, 
experienced prolonged stable disease as best response, and ultimately discontinued 
treatment due to clinical symptomatic deterioration.  
Antitumor Activity in Patients With Neuroblastoma 
Seven patients with neuroblastoma were evaluable for efficacy. The current 
study was initiated prior to the publication of the revised INRC guidelines [24]; however, 
post hoc analyses demonstrated that, using revised INRC criteria, 2 patients with 
neuroblastoma had minor response due to robust decreases in Curie score of 60% and 
63%, but only stable disease by RECIST. One patient had stable disease, and 4 
patients had progressive disease. 
 
Discussion  
The phase I portion of this study met its primary objective by determining the 
MTD/RP2D of weekly nab-paclitaxel in pediatric patients with recurrent/refractory solid 
tumors. Weekly nab-paclitaxel at the recommended dose of 240 mg/m2 resulted in a 
manageable safety profile. As in adults, the most common AEs were hematologic in 
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nature. Peripheral neuropathy and hand-foot syndrome were rare, and no central 
neurotoxicity occurred. Per RECIST, responses were observed in 5 of 58 patients (9%); 
all responses occurred at ≥210 mg/m2 (the response rate for these doses combined was 
21%). Stable disease was achieved in 13 patients (22%) in the total cohort. Two of 7 
patients (28%) with neuroblastoma had an INRC-defined minor response with 
significant decreases in Curie score.  
The nab-paclitaxel RP2D was defined as 240 mg/m2 based on the totality of 
safety data, despite not meeting protocol-defined DLT criteria at the highest nab-
paclitaxel dose level tested (270 mg/m2). This RP2D is higher than that of adult doses, 
possibly related to the lower incidence of peripheral neuropathy compared with the adult 
population, which is often dose-limiting. nab-Paclitaxel is not formulated in a chemical 
solvent, that is at least a partial contributor to neurotoxicity; this allows for achievement 
of higher dosages. Hematologic toxicity was manageable but led to frequent dose 
reductions and delays. Although cross-trial comparisons should be made with caution 
due to differences in study populations and designs, the overall incidence of grade 3/4 
treatment-emergent peripheral neuropathy reported in the current study (3%) was lower 
than the rate of grade 3 treatment-related sensory neuropathy reported in a phase III 
trial of women with breast cancer receiving nab-paclitaxel 260 mg/m2 monotherapy 
every 3 weeks [14]. Skin toxicity in this study was not dose limiting and occurred only at 
the highest dose level examined.  
Pharmacokinetic analyses showed that the increase in blood exposure to nab-
paclitaxel was approximately dose proportional in pediatric patients with solid tumors. Of 
note, the RP2D of nab-paclitaxel 240 mg/m2 qw3/4 determined from this study in an 
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advanced and heavily pretreated pediatric cancer population is nearly double that of the 
dose tested (125 mg/m2) on the same schedule in a recent phase III trial in adult women 
with early breast cancer [18]. However, the dose-adjusted blood exposure (AUC and 
Cmax) to nab-paclitaxel in the current study was similar to that observed in adult patients 
with advanced solid tumors [25].  
In conclusion, nab-paclitaxel 240 mg/m2 qw3/4 had a manageable toxicity profile 
and demonstrated preliminary clinical activity in pediatric patients with solid tumors, and 
results from the phase I portion of this study warrant further investigation of nab-
paclitaxel in the pediatric population. The phase II portion of this study evaluating nab-
paclitaxel monotherapy at the established RP2D in patients with neuroblastoma, 
rhabdomyosarcoma, and Ewing sarcoma is currently enrolling.  
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Table 1. Patient Characteristics: Safety Populationa   
Characteristic 
nab-Paclitaxel Dose 
120 mg/m2 
n = 16 
150 mg/m2 
n = 8 
180 mg/m2 
n = 14 
210 mg/m2 
n = 11 
240 mg/m2 
n = 8 
270 mg/m2 
n = 7 
Total 
N = 64 
Dose-determining set, n 6 6 6 6 6 7 37 
Age, median, years 
2-11 years, n (%) 
12-17 years, n (%) 
12.5 
6 (38) 
10 (63) 
14.0 
2 (25) 
6 (75) 
11.0 
7 (50) 
7 (50) 
9.0 
6 (55) 
5 (45) 
12.0 
3 (38) 
5 (63) 
13.0 
3 (43) 
4 (57)  
12.0 
27 (42) 
37 (58) 
Male, n (%) 7 (44) 4 (50) 5 (36) 4 (36) 7 (88) 4 (57) 31 (48) 
Lansky/Karnofsky PS, n (%) 
90-100 
70-80 
 
12 (75) 
4 (25) 
 
5 (63) 
3 (38) 
 
9 (64) 
5 (36) 
 
9 (82) 
2 (18) 
 
5 (63) 
3 (38) 
 
4 (57) 
3 (43) 
 
44 (69) 
20 (31) 
Solid tumor type, n (%) 
Neuroblastoma 
Rhabdomyosarcoma 
Ewing sarcoma 
Osteosarcoma 
Otherb 
 
2 (13) 
3 (19) 
3 (19) 
4 (25) 
4 (25) 
 
0 
1 (13) 
2 (25) 
1 (13) 
4 (50) 
 
2 (14) 
7 (50) 
2 (14) 
0 
3 (21) 
 
4 (36) 
2 (18) 
1 (9) 
1 (9) 
3 (27) 
 
2 (25) 
1 (13) 
1 (13) 
1 (13) 
3 (38) 
 
0 
0 
4 (57) 
1 (14) 
2 (29) 
 
10 (16) 
14 (22) 
13 (20) 
8 (13) 
19 (30) 
Prior treatment lines, median 
(range), n 
3 
(1-8) 
3 
(1-7) 
3 
(1-7) 
3 
(1-10) 
3 
(1-5) 
3 
(2-4) 
3 
(1-10) 
NOS, not otherwise specified; PC, performance status.  
a Includes all patients who received ≥1 dose of nab-paclitaxel. b Includes patients with adrenocortical carcinoma, clear cell 
sarcoma of the kidney, desmoplastic small round cell tumor, hepatoblastoma, hepatocarcinoma, immature ovarian teratoma, 
left adrenocortical carcinoma, left renal tumor with pulmonary metastases, nasopharyngeal carcinoma, sarcoma NOS, Wilms 
tumor, and yolk sac tumor. 
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Table 2. Treatment-Emergent Adverse Events: Safety Populationa  
AEs, n (%) 
nab-Paclitaxel Dose 
120 mg/m2 
n = 16 
150 mg/m2 
n = 8 
180 mg/m2 
n = 14 
210 mg/m2 
n = 11 
240 mg/m2 
n = 8 
270 mg/m2 
n = 7 
All Treated 
Patients 
N = 64 
Grade 3/4 AEs reported in ≥20% of patients in ≥1 dosing cohort 
Hematologicb 
Neutropenia 4 (25) 1 (13) 3 (21) 6 (55) 4 (50) 5 (71) 23 (36) 
Leukopenia 3 (19) 1 (13) 6 (43) 5 (45) 4 (50) 4 (57) 23 (36) 
Lymphopenia 3 (19) 1 (13) 2 (14) 3 (27) 3 (38) 4 (57) 16 (25) 
Nonhematologic 
Skin pain 0 0 0 0 0 2 (29) 2 (3) 
Hand-foot syndrome 0 0 0 0 0 2 (29) 2 (3) 
Hyponatremia 1 (6) 3 (38) 0 0 0 0 4 (6) 
Hypotension 0 2 (25) 1 (7) 0 0 0 3 (5) 
TEAEs of special interest  
Peripheral neuropathy 0 0 0 0 1 (13) 1 (14) 2 (3) 
Arthralgia 0 1 (13) 0 2 (18) 0 0 3 (5) 
Nausea 0 1 (13) 0 0 0 1 (14) 2 (3) 
AE, adverse event; TEAE, treatment-emergent adverse event.  
a Safety population includes all patients who received ≥1 dose of nab-paclitaxel. b Hematologic events reported from 
laboratory values collected on dosing days. 
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Table 3. Treatment Exposure: Safety Populationa   
Parameter 
nab-Paclitaxel Dose 
120 mg/m2 
n = 16 
150 mg/m2 
n = 8 
180 mg/m2 
n = 14 
210 mg/m2 
n = 11 
240 mg/m2 
n = 8 
270 mg/m2 
n = 7 
Total 
N = 64 
Total number of 
treatment cycles, 
median (range) 
2 (1-5) 2 (1-12) 2 (1-8) 2 (1-5) 3 (1-5) 2 (1-10) 2 (1-12) 
Relative dose 
intensity,  
median (range), %b 
100.0 
(97-111) 
99.6 
(80-116)  
99.5 
(73-107) 
99.9 
(89-107) 
95.8 
(77-101) 
94.8 
(64-101) 
99.6 
(64-116) 
Cumulative dose, 
median, mg/kg 
715.6 816.3 1074.5 1248.4 1806.0 1536.5 1004.6 
Patients with ≥1 
treatment-emergent 
AE leading to dose 
reduction, n (%)c 
0  1 (13) 2 (14) 1 (9) 3 (38) 3 (43) 10 (16) 
Patients with ≥1 
treatment-emergent 
AE leading to 
discontinuation, n 
(%)c 
4 (25) 0 2 (14) 1 (9) 2 (25) 2 (29) 11 (17) 
AE, adverse event. 
a Includes all patients who received ≥1 dose of nab-paclitaxel. b Defined as 100 × the average dose intensity/the planned dose 
intensity. c Over all cycles. 
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Table 4. Best Response Per RECIST in Efficacy-Evaluable Populationa 
 
Response, n (%) 
CR PR SD PD Clinical 
Symptomatic 
Deterioration  
All ≥16 wks 
Tumor type 
Neuroblastoma (n = 7) 0 0 2 (28.6) 1 (14.3) 2 (28.6) 3 (42.9) 
Rhabdomyosarcoma (n = 12) 0 1 (8.3) 1 (8.3) 0 9 (75.0) 1 (8.3) 
Ewing sarcoma (n = 12) 1 (8.3) 1 (8.3) 3 (25.0) 2 (16.7) 6 (50.0) 1 (8.3) 
Osteosarcoma (n = 8) 0 0 1 (2.5) 0 6 (75.0) 1 (12.5) 
Wilms tumor (n = 4) 0 0 0 0 4 (100.0) 0 
Otherb (n = 15) 0 2 (13.3) 6 (40.0) 2 (13.3) 6 (40.0) 1 (6.7) 
nab-Paclitaxel dose, mg/m2  
120 (n = 14) 0 0 2 (14.3) 0 10 (71.4) 2 (14.3) 
150 (n = 8) 0 0 2 (25.0) 2 (25.0) 5 (62.5) 1 (12.5) 
180 (n = 12) 0 0 4 (33.3) 1 (8.3) 7 (58.3) 1 (8.3) 
210 (n = 10) 1 (10.0) 0 2 (20.0) 1 (10.0) 5 (50.0) 2 (20.0) 
240 (n = 7) 0 3 (42.9) 1 (14.3) 0 2 (28.6) 1 (14.3) 
270 (n = 7) 0 1 (14.3) 2 (28.6) 1 (14.3) 4 (57.1) 0  
All efficacy-evaluable 
patients (n = 58) 
1 (1.7) 4 (6.9) 13 (22.4) 5 (8.6) 33 (56.9) 7 (12.1) 
CR, complete response; NOS, not otherwise specified; PD, progressive disease; PR, partial response; RECIST, 
Response Evaluation Criteria In Solid Tumors; SD, stable disease; wk, week. 
a Included all treated patients who met study eligibility criteria, received ≥1 dose of nab-paclitaxel, and had a baseline 
efficacy assessment and either ≥1 postbaseline assessment or symptomatic deterioration. b Includes patients with 
adrenocortical carcinoma, clear cell sarcoma of the kidney, desmoplastic small round cell tumor, hepatoblastoma, 
hepatocarcinoma, immature ovarian teratoma, left adrenocortical carcinoma, left renal tumor with pulmonary metastases, 
nasopharyngeal carcinoma, sarcoma NOS, Wilms tumor, and yolk sac tumor. 
 
nab-Paclitaxel in Pediatric Patients With Solid Tumors - Final for Submission 
 
19 
 
Figure 1. Patient Enrollment and Evaluable Populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 patients signed ICF 
65 patients fulfilled  
eligibility criteria 
8 screening failures 
64 patients received 
 treatment 
1 patient withdrew per 
parent/guardian 
before starting treatment 
37 patients treated in dose-determining set in 6 nab-P 
dose levels (120, 150, 180, 210, 240 and 270 mg/m
2
);  
DLTs seen at dose levels 120 mg/m2 (n = 1) and 270 
mg/m2 (n = 1)  
27 patients treated while 
no cohort placement 
was available 
Safety set = 64 patients 
Efficacy set = 58 patients 
6 patients not part of  
efficacy set due to 
withdrawal by 
parent/guardian (n = 2), 
adverse event (n = 3), and 
no baseline disease 
assessment (n = 1)  
Radiographic response-evaluable patients = 51 patients by RECIST;  
7 of these patients had neuroblastoma and were also evaluated by  
Curie score 
7 patients not evaluable  
by RECIST due to clinical 
symptomatic deterioration 
before first postbaseline 
assessment   
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DLT, dose-limiting toxicity; ICF, informed consent form; nab-P, nab-paclitaxel; PD, progressive disease; RECIST, 
Response Evaluation Criteria In Solid Tumors. 
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Supplemental Methods  
Efficacy was evaluated in all treated patients who met study eligibility criteria, received 
≥1 dose of nab-paclitaxel, and had a baseline efficacy assessment and either ≥1 
postbaseline assessment or symptomatic deterioration. Patients with neuroblastoma 
were also assessed with 123metaiodobenzylguanidine (MIBG) scintigraphy using the 
Curie score [23]. For Curie score assessment in patients with neuroblastoma, an 
absolute score was calculated based on the sum of lesions detected throughout the 
body, and a relative score was calculated by dividing the absolute score at each 
assessment time point by the corresponding pretreatment overall score. As defined in 
the protocol, response was classified as complete if the postscreening absolute score = 
0 (all areas of uptake on MIBG scan completely resolved), partial if the relative score 
was ≥ 0.1 to ≤ 0.5 (lesions strongly reduced), stable disease if the relative score was > 
0.5 (lesions weakly but significantly reduced), and progressive disease if new lesions 
were detected on MIBG scan, regardless of relative score. Overall response rate was 
defined as the number of patients achieving either a complete or partial response while 
receiving study therapy (confirmed ≥ 4 weeks after response criteria were first met) 
divided by the number of patients available for the analysis.  
Response was assessed by investigator using computed tomography or magnetic 
resonance imaging at screening and every 8 weeks per Response Evaluation Criteria In 
Solid Tumors (RECIST) to < 1 (lesions not reduced) and progressive disease if new 
lesions were identified on MIBG scan, regardless of relative score. The study protocol 
was completed before recent revisions to INRC criteria [24]. After publication of the new 
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INRG response criteria, a post hoc assessment of patients with neuroblastoma was 
conducted using these revised criteria instead of the protocol-defined criteria. 
